We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

108 hedge funds and large institutions have $737M invested in Karyopharm Therapeutics in 2018 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 43 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

105% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 21

78% more capital invested

Capital invested by funds: $415M → $737M (+$322M)

23% more funds holding

Funds holding: 88 → 108 (+20)

8% more call options, than puts

Call options by funds: $616K | Put options by funds: $572K

0.65% more ownership

Funds ownership: 4.15% → 4.8% (+0.65%)

Holders
108
Holders Change
+20
Holders Change %
+22.73%
% of All Funds
2.47%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
32
Increased
43
Reduced
21
Closed
10
Calls
$616K
Puts
$572K
Net Calls
+$44K
Net Calls Change
+$98K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$78.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$24M
3
State Street
State Street
Massachusetts
+$22.2M
4
BlackRock
BlackRock
New York
+$21.4M
5
PAI
Palo Alto Investors
California
+$16.2M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$24.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.51M
3
ACA
Avoro Capital Advisors
New York
-$7.52M
4
Millennium Management
Millennium Management
New York
-$3.84M
5
JP Morgan Chase
JP Morgan Chase
New York
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
DAM
26
Doheny Asset Management
California
$4.81M +$890K +3,597 +24%
Charles Schwab
27
Charles Schwab
California
$4.37M +$1.47M +5,948 +53%
PAM
28
Panagora Asset Management
Massachusetts
$3.95M +$1.36M +5,513 +55%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$3.64M +$774K +3,128 +28%
Citadel Advisors
30
Citadel Advisors
Florida
$3M +$1.36M +5,494 +88%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$2.91M -$66.5K -269 -2%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$2.66M +$2.58M +10,433 New
MOACM
33
Mutual of America Capital Management
New York
$2.64M – – –
MCM
34
Moore Capital Management
New York
$2.55M +$2.47M +10,000 New
Renaissance Technologies
35
Renaissance Technologies
New York
$2.34M +$2.27M +9,193 New
JP Morgan Chase
36
JP Morgan Chase
New York
$2.06M -$2.77M -11,188 -58%
SH
37
Sandia Holdings
Connecticut
$2.03M +$1.97M +7,983 New
USAA
38
United Services Automobile Association
Texas
$1.93M +$445K +1,799 +31%
Morgan Stanley
39
Morgan Stanley
New York
$1.84M -$649K -2,623 -27%
ARTA
40
A.R.T. Advisors
New York
$1.82M +$1.52M +6,153 +623%
Allianz Asset Management
41
Allianz Asset Management
Germany
$1.68M +$1.63M +6,588 New
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.45M +$346K +1,400 +33%
Bank of America
43
Bank of America
North Carolina
$1.3M +$520K +2,104 +70%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.26M +$331K +1,339 +37%
AllianceBernstein
45
AllianceBernstein
Tennessee
$1.05M -$176K -713 -15%
Jacobs Levy Equity Management
46
Jacobs Levy Equity Management
New Jersey
$1.03M +$145K +586 +17%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$916K +$267K +1,080 +43%
Citigroup
48
Citigroup
New York
$882K +$505K +2,042 +144%
BC
49
Birchview Capital
Vermont
$850K +$824K +3,333 New
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$839K +$386K +1,560 +90%
1
2
3 4 5

KPTI Hedge Fund Activity: Q2 2018 in Review

108 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2018, worth a combined $737M — up 78% from $415M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new KPTI positions and 10 closed out — a net gain of 22 holders — while 43 added to existing stakes and 21 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $78.6M. The largest seller was Fidelity Investments, cutting an estimated $24.6M.

  • 108 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2018, up from 88 in Q1 2018.
  • Funds reported $737M of Karyopharm Therapeutics stock for Q2 2018, up 78% quarter-over-quarter.
  • 32 funds opened new Karyopharm Therapeutics positions in Q2 2018 and 10 closed out, a net change of +22 holders.
  • The largest Karyopharm Therapeutics buyer in Q2 2018 was Consonance Capital Management, an estimated $78.6M added.
  • The largest Karyopharm Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $24.6M sold.

Based on aggregated 13F filings for Q2 2018.